Barclays
TXG icon

Barclays’s 10x Genomics TXG Stock Holding History

Barclays’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Buy
34,498
+5,400
+19% +$142K ﹤0.01% 2624
2026
Q1 		$618K Sell
29,098
-288,884
-91% -$5.78M ﹤0.01% 3062
2025
Q4 		$5.19M Sell
317,982
-187,409
-37% -$2.83M ﹤0.01% 2194
2025
Q3 		$5.91M Sell
505,391
-471,597
-48% -$6.15M ﹤0.01% 2064
2025
Q2 		$11.3M Buy
976,988
+191,158
+24% +$1.74M ﹤0.01% 1489
2025
Q1 		$6.86M Sell
785,830
-5,127
-0.6% -$64.6K ﹤0.01% 1671
2024
Q4 		$11.4M Buy
790,957
+188,421
+31% +$2.97M ﹤0.01% 1479
2024
Q3 		$13.6M Buy
602,536
+80,579
+15% +$1.67M ﹤0.01% 1269
2024
Q2 		$10.2M Buy
521,957
+464,221
+804% +$12.2M ﹤0.01% 1187
2024
Q1 		$2.17M Sell
57,736
-208,562
-78% -$9.16M ﹤0.01% 2491
2023
Q4 		$14.9M Buy
266,298
+244,099
+1,100% +$10.6M 0.01% 1227
2023
Q3 		$916K Buy
22,199
+584
+3% +$30.4K ﹤0.01% 2389
2023
Q2 		$1.21M Buy
21,615
+9,970
+86% +$540K ﹤0.01% 2187
2023
Q1 		$650K Sell
11,645
-160,027
-93% -$7.47M ﹤0.01% 3074
2022
Q4 		$6.26M Buy
171,672
+145,505
+556% +$4.76M ﹤0.01% 1466
2022
Q3 		$745K Buy
26,167
+3,815
+17% +$145K ﹤0.01% 2436
2022
Q2 		$1.01M Sell
22,352
-18,061
-45% -$937K ﹤0.01% 2336
2022
Q1 		$3.07M Buy
+40,413
New +$3.54M ﹤0.01% 1539

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's TXG Position: Q2 2026 in Review

Barclays increased its 10x Genomics (TXG) stake by 19% in Q2 2026, buying an estimated $142K and bringing the position to 34,498 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2624.

Barclays first reported a position in TXG in Q1 2022 and has held it in 18 quarters since. The position peaked at $14.9M in Q4 2023. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Barclays held 34,498 shares of 10x Genomics worth $1.32M as of Q2 2026.
  • Barclays bought 5,400 10x Genomics shares in Q2 2026, an estimated $142K.
  • 10x Genomics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2624 holding.
  • Barclays first reported a position in 10x Genomics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's 10x Genomics position peaked at $14.9M in Q4 2023.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.